PDCD1LG2 and cancer: JNJ-605 also strongly counteracted the induction of PD-L2 by IFNγ: upon 48 h of treatment, the ligand exposed at the surface of EBC-1 and Hs746T cancer cells returned to basal levels (Fig. 3c).